About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, May 26th, 2015

The QualityStocks
Daily Stock List


Montalvo Spirits, Inc. (TQLA)

SmallCapVoice, TopPennyStockMovers, OTC Markets Group, SuperStockTips, and PennyStocks24 reported earlier on Montalvo Spirits, Inc. (TQLA), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Montalvo Spirits, Inc. develops, markets, and distributes premium alcoholic beverages. Its initial offering is the award-winning Montalvo Tequila. Montalvo Spirits’ plan is to concentrate on artisanal spirit brands with a tradition of excellence and quality. The Company’s mission is to expand its current portfolio through the incubation of new brands and the acquisition of existing, complementary brands. Montalvo Spirits is based in Moorpark, California and the Company’s shares trade on the OTC Markets’ OTCQB.

Montalvo Tequila was awarded a Gold Medal in the Tequila Blanco category for the 2014 Spirits of the Americas Tasting Competition, held by the IWSC Group. The IWSC Group is the world leader in organizing wine and spirit competitions around the world. Furthermore, Montalvo Tequila received medals in the Tequila Reposado and Tequila Anejo categories.  Brands are judged on five essential characteristics. These include appearance, aromatics, flavor, mouth-feel, and finish.

Montalvo Spirits has appointed Southern Wine & Spirits of America, Inc. as the exclusive distributor of Montalvo Tequila in the State of California. The Company will continue its distribution efforts in California by way of Southern Wine & Spirits.

Southern Wine & Spirits of America is the nation's largest wine and spirits distributor and broker. It has operations in 35 markets. Southern Wine & Spirits of America employs close to 14,500 team members on a national basis.
Montalvo Spirits has established Cannabis Beverage Group, Inc. (CBG) as a wholly-owned subsidiary. A Colorado corporation, CBG is pursuing the development, marketing, and distribution of cannabis-based beverages. This includes sodas, teas, energy drinks, liqueurs, and elixirs.

CBG is seeking non-THC containing cannabis beverages, which can be legally purchased throughout the United States. Its strategy for entry into the industry includes the development of new brands and the potential acquisition, partnership, or distribution arrangements with brands that are now in the market. In addition, CBG started gathering regulatory information regarding the potential partnership or acquisition of properly licensed companies in the medical marijuana beverage industry.

This past April, Montalvo Spirits announced its partnership with MLB’s The San Diego Padres. The partnership brings Montalvo Tequila into Petco Park, home of the Padres. Elements include The Rail presented by Montalvo Tequila and the Montalvo Tequila Bar on the rooftop of the Western Metal Supply Co. building.

Montalvo Spirits, Inc. (TQLA), closed Tuesday's trading session at $0.022, up 0.46%, on 73,750 volume with 8 trades. The average volume for the last 60 days is 153,083 and the stock's 52-week low/high is $0.0156/$0.136.

Communication Intelligence Corp. (CICI)

SmallCapVoice reported recently on Communication Intelligence Corp. (CICI), TheMicrocapNews, PennyTrader Publisher, Top Gun, and The Stock Psycho did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Communication Intelligence Corp. (CIC) is a leading supplier of electronic signature products and the recognized leader in biometric signature verification. The Company enables enterprises to attain truly paperless workflow in their electronic business processes. It does so through providing multiple signature technologies across almost all enterprise, desktop, as well as mobile environments as a seamlessly integrated platform for ad-hoc and fully automated transactions. CIC lists on the OTC Markets Group’s OTCQB. The Company’s has its corporate headquarters in Redwood Shores, California.

Fundamentally, CIC is a foremost supplier of electronic signature and other software solutions. These enable secure and cost-effective management of document-based digital transactions. The Company’s solutions cover a broad assortment of functionality and services. These include electronic signatures, biometric authentication, and simple-to-complex workflow management. CIC's platform can be deployed both on-premise and as a cloud-based service. The platform can easily transition between deployment models.

CIC provides digital transaction management (DTM) software allowing for fully digital business processes.  So far, it has chiefly delivered biometric and electronic signature solutions to channel partners and end-user customers in the financial services industry.

The Company’s solutions are available in Software-as-a-Service (SaaS) and on-premise delivery models. Its solutions provide "straight-through-processing." This has the ability to grow customer revenue through enhancing user experience. Furthermore, CIC’s solutions can reduce costs through paperless and virtually error-free electronic transactions, which can be completed significantly faster than paper-based procedures.

This month, CIC reported revenue of $446,000 for the three months ended March 31, 2015. This represents an increase of $145,000 or 48 percent, versus total revenue of $301,000 for the same quarter the prior year. For the quarter ended March 31, 2015, the net loss attributable to common stockholders was $2,260,000. This represents an increase of $204,000, or 10 percent, versus a net loss attributable to common stockholders of $2,056,000 for the same quarter in the prior year.

The increase was mainly because of a higher non-cash accretion of beneficial conversion feature on preferred stock and preferred stock dividends, offset by the increase in revenue, net of an increase in operating expenses, versus the same quarter in the year prior.

Mr. Philip Sassower, Communication Intelligence Chairman and CEO, said, “Thanks to increases in product, service and maintenance sales, our average quarterly revenue, over the comparable trailing twelve month periods, has improved, while our operating expenses, net of non-cash charges, largely have remained flat. We are aggressively pursuing recurring revenue both in the US and Europe and will continue this effort.”

Communication Intelligence Corp. (CICI), closed Tuesday's trading session at $0.014, down 17.65%, on 479,989 volume with 18 trades. The average volume for the last 60 days is 59,040 and the stock's 52-week low/high is $0.007/$0.0445.

Rich Pharmaceuticals, Inc. (RCHA)

PennyStockRumors.net, Actual Gains, PricelessPennyStocks, 007 Stock Chat, PennyStockSpy, and TopPennyStockMovers reported earlier on Rich Pharmaceuticals, Inc. (RCHA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rich Pharmaceuticals, Inc. is a Biopharmaceutical Company that lists on the OTC Bulletin Board. It is developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. It is concentrating on the development of its lead product, RP-323 (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. Rich’s goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals is headquartered in Beverly Hills, California.

The design of the Company’s RP-323 is to treat blood and cancer related diseases through non-evasive outpatient facilities. Overall, it is focusing on the discovery, development, and commercialization of drugs to treat unmet medical needs in oncology that function at the DNA level. Rich’s corporate mission is to develop these small-molecule compounds to treat cancer and stroke in patients with the greatest unmet medical needs.

Rich Pharmaceuticals has entered into an agreement with Richard L. Chang Holdings, LLC, based in New Jersey, for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin's Lymphoma. Hodgkin Lymphoma is a cancer of the immune system, marked by the presence of a kind of cell called the Reed-Sternberg cell.

With this agreement, Rich Pharmaceuticals will obtain complete ownership and all interest in the indication, patents, and intellectual property (IP) related to treatment of Hodgkin's Lymphoma, utility patent application number 61998397, entitled Compositions And Methods Of Use Of Phorbol Esters For The Treatment Of Hodgkin's Lymphoma.

Rich Pharmaceuticals has entered into a Letter of Intent (LOI) with The Faculty of Medicine at Khon Kaen University, Thailand to conduct clinical trials using the Company’s lead molecule, RP-323 in treating Acute Myelocytic Leukemia (AML) patients. The estimation is that the clinical studies will include 36 patients and 3 separate sites. Acute Myelocytic Leukemia (AML), also known as Acute Myelogenous Leukemia, is the most common acute leukemia kind that affects adults.

Rich Pharmaceuticals, Inc. (RCHA), closed Tuesday's trading session at $0.0004, down 20.00%, on 58,074,001 volume with 50 trades. The average volume for the last 60 days is 47,535,651 and the stock's 52-week low/high is $0.0004/$0.15.

Holloman Energy Corp. (HENC)

Wall Street Resources reported earlier on Holloman Energy Corp. (HENC), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Holloman Energy Corp. is focusing on oil and gas exploration and production (E&P) in Australia’s Cooper/Eromanga Basin. The Company’s Cooper Basin licenses include interests in PEL 112 and PEL 444, which presently consist of 3,444 km2 (approximately 850,000 gross acres, 413,000 net acres) on the prolific Western Margin of Australia's Cooper/Eromanga Basin. Holloman has a professional strategy to use capable joint venture (JV) partners in its exploration efforts. OTCQB-listed, Holloman Energy has its corporate head office in Houston, Texas.

Oil in the Cooper/Eromanga Basin, to date, has usually been between 40 to 55⁰ API, with very low gas-oil ratios that are frequently classified as light crude oil that requires less processing and normally commands premium pricing. The lifting costs for oil in the Cooper/Eromanga Basin are reported to be one of the most competitive worldwide.

The Company’s PEL 112 and PEL 444 have access to nearby equipment and infrastructure. These include a network of pipeline, a central processing plant, as well as three major seaports. The access to this infrastructure provides a short and less expensive route to market future discoveries.

PEL 444 consists of 2,358 square kilometers (582,674 gross acres). PEL 112 consists of 1,086 square kilometers (268,356 gross acres). Major E&P companies participating in Holloman Energy’s surrounding blocks include Senex Energy, Drillsearch Energy, and Strike Energy.

Last week, Holloman Energy received notice that Terra Nova had terminated its Farm-In Agreement on Petroleum Exploration Licenses (PELs) 112 and 444. Because of the Farm-In termination, Holloman Energy will no longer be obligated to transfer any additional working interest in PEL 112 or PEL 444 to Terra Nova. Holloman Energy is in the process of revisiting drilling plans. The Company has already started contacting potential drillers.

Mr. Mark Stevenson, Chief Executive Officer of Holloman Energy (HENC), said, "We consider the Terra Nova relationship an overall success for HENC. Although we are disappointed to see the Terra Nova partnership come to an end, we are pleased with the benefits the Farm-In has provided. During the Farm-In period we have obtained valuable scientific information on both PEL 112 and PEL 444 which we believe will prepare HENC for near-term successful exploration."

Holloman Energy Corp. (HENC), closed Tuesday's trading session at $0.27, up 17.39%, on 190,298 volume with 35 trades. The average volume for the last 60 days is 45,995 and the stock's 52-week low/high is $0.12/$0.50.

Enerpulse Technologies, Inc. (ENPT)

OTC Markets Group reported previously on Enerpulse Technologies, Inc. (ENPT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enerpulse Technologies, Inc. develops and manufactures ultra-high performance, low emissions ignition products through the application of pulse power technology. Through its wholly-owned subsidiary, Enerpulse, Inc., it designs, develops, manufactures, and markets an energy and efficiency enhancing product in the automotive industry under the Pulstar® brand name. Enerpulse Technologies’ shares trade on the OTC Bulletin Board. Established in 2004, the Company is based in Albuquerque, New Mexico.

Enerpulse Technologies provides products to three markets. These are Automotive original equipment manufacturers (OEMs); NatGas Fueled SI Engines (NG, CNG, LNG, LPG, Bio-Gas) – Stationary & Vehicular Applications; as well as the Automotive/Power Sports Aftermarket under the brand name Pulstar®.

Pulstar® with PlasmaCore Pulse Plug uses an integrated capacitor that stores and compresses electrical energy to intensify the ignition spark in internal combustion engines (ICE). The process increases fuel economy and engine performance. Pulse plugs feature an innovative capacitor-based circuit.

This circuit captures energy typically wasted by spark plugs and generates a spark with 20,000 times greater energy than any spark plug. Electrical energy from the engine’s ignition coil is stored in the built-in capacitor. At the precise moment required, that energy is released in a powerful and fast (two nanosecond) high-energy pulse.

Pulstar® with PlasmaCore spark plug is created with Enerpulse Technologies’ patented Nano-Plasma Assisted Combustion (n-PAC®) technology. This technology intensifies the ignition spark. This increases fuel economy, reduces tailpipe emissions, and improves engine performance.

The Company’s Pulstar® with PlasmaCore aftermarket products can be utilized in all spark-ignited IC engines. This includes passenger cars, light trucks, commercial trucks, and also motorcycles. Its Pulstar® with PlasmaCore pulse plugs fit directly into existing IC engine ignition systems and use existing fuel delivery infrastructures.

Last week, Enerpulse Technologies announced its financial results for Q1 ended March 31, 2015. Selected Q1 highlights include Sales Revenue up 13 percent over the prior year same period. Gross Profit was up 733 percent from $6,000 for the three months ended March 31, 2014 to $53,000 for the three months ended March 31, 2015.

Margins improved considerably over the prior year same period from 6.5 percent to 48 percent. This was because of several factors, such as better utilization of production labor and direct overhead for the period ending March 31, 2015.

Enerpulse Technologies, Inc. (ENPT), closed Tuesday's trading session at $0.075, up 7.14%, on 3,950 volume with 2 trades. The average volume for the last 60 days is 39,265 and the stock's 52-week low/high is $0.04/$0.70.


The QualityStocks
Company Corner


Growblox Sciences, Inc. (GBLX)

The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.31775, off by 2.38%, on 50,477 volume with 29 trades. The stock’s average daily volume over the past 60 days is 63,941, and its 52-week low/high is $0.151/$3.49.

Growblox Sciences, Inc. announced today the receipt of production-model GrowBLOX™ units for both GB Sciences Nevada (GBSN) and GB Sciences Puerto Rico (GBS PR). Validation of the GrowBLOX™ technology suite will include the development of a remote monitoring and diagnostic services program, as well as tissue-culture propagation and plant-genotype, cryogenic banking services. In addition, GBS PR will be responsible for implementing the GBLX quality management system to assure that all aspects of the cultivation of medical cannabis in the GrowBLOX™ technology suite conform to Current Good Manufacturing Practices (or cGMP).

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer

Growblox Sciences, Inc. Company Blog

Growblox Sciences, Inc. News:

GrowBLOX Announces Deployment of Commercial Units

Growblox Sciences, Inc. (GBLX) is “One to Watch”

Growblox Announces Commercialization Initiative and Financing

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0015, up 25.00%, on 4,352,000 volume with 35 trades. The stock’s average daily volume over the past 60 days is 3,864,098, and its 52-week low/high is $0.0012/$0.1874.

Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power Inc. Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors

Well Power - Letter from President to Shareholders

Well Power Inc. to host second webinar on proprietory micro-refinery technology

Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.05, up 11.11%, on 49,700 volume with 2 trades. The stock’s average daily volume over the past 60 days is 73,668, and its 52-week low/high is $0.0423/$0.22.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling Groups Blended Schools Network Powers Mountain House High Schools Personalized Learning; BSN Curriculum Achieves California A-G Certification

Sibling Group's Urban Planet Mobile Deepens Strategic Partnership With Imagine Easy Solutions and EasyBib; UPMs Writing Planet Essay Scoring Solution to Be Offered Across All Imagine Easy Citation Websites Worldwide

Strategic Partner Shenzhen Times Increases Stake in Sibling Group; $5,500,000 Warrant Exercise to Fund Growth Initiatives

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $9.00, even for the day, on 550 volume with 3 trades. The stock’s average daily volume over the past 60 days is 174, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

Car Monkeys Group (CKMY)

The QualityStocks Daily Newsletter would like to spotlight Car Monkeys Group (CKMY). Today, Car Monkeys Group closed trading at $0.15, even for the day. The stock’s average daily volume over the past 60 days is 7,814, and its 52-week low/high is $0.05/$5.00.

Car Monkeys Group (CKMY), via CarMonkeys.com, is one of the largest and fastest growing online cars, vans and SUV parts distributors in the United States. Founded in 2010, the Wyckoff, New Jersey-based company formerly was known as Delaine Corporation and changed its name to Car Monkeys Group in February 2015.

With access to hundreds of thousands of parts, Car Monkeys sells used, high-quality, low-mileage automotive parts to consumers, retailers, truck and car fleet owners and auto repair facilities looking for a wide range of vehicle makes and models. Customers have access to a Part Finder section that helps them easily navigate and quickly locate the right parts they need.

Striving to provide customers a quick, hassle-free and convenient shopping experience, all parts ordered through CarMonkeys.com ship from one of the company’s numerous distributors and auto dismantling centers straight to the customer or their mechanic. Advantages such as a five-year unlimited mileage warranty, zero shipping costs, and a generous return policy further contribute to the increasing popularity of the Car Monkeys brand.

Automotive recycling plays a substantial role in the preservation of natural resources and reduction of demand for landfill space. According to the Automotive Recyclers Association, approximately 95% of vehicles retired from use are processed for recycling, saving an estimated 85 million barrels of oil that would have been used to manufacture new or replacement parts. As a rapidly growing and trusted automotive recycling company, Car Monkeys is positioned as a leading player in the broader $22 billion North American automotive recycling industry. Disclaimer

Car Monkeys Group Company Blog

Car Monkeys Group News:

Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services

Car Monkeys Group (CKMY) is “One to Watch”

Car Monkeys Group (CKMY) Continues Growth as one of the Country’s Largest Online Automobile Parts Distributors


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251